Welcome to our dedicated page for Shuttle Pharmaceuticals Holdings SEC filings (Ticker: SHPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Shuttle Pharmaceuticals Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Shuttle Pharmaceuticals Holdings's regulatory disclosures and financial reporting.
Shuttle Pharmaceuticals Holdings has filed a Form D notice for an exempt securities offering under Rule 506(b). The company has successfully raised $4,250,000 through the offering, which was completed on June 20, 2025, with no remaining amount to be sold.
Key details of the offering:
- Securities offered include equity, options/warrants, and securities to be acquired upon exercise
- WestPark Capital served as broker-dealer with sales commissions of $170,000
- Total of 1 investor participated in the offering
- Offering not intended to last more than one year
The company's leadership includes Christopher Cooper (CEO), Peter Dritschilo (President/COO), Mira Jung (Chief Scientific Officer), Tyvin Rich (Chief Medical Officer), and Timothy Lorber (CFO). The pharmaceutical company is headquartered in Gaithersburg, Maryland, and was incorporated in Delaware over five years ago.
Shuttle Pharmaceuticals Holdings (NASDAQ:SHPH) has entered into a private placement agreement with an accredited investor on June 20, 2025. The company will sell 21,924 shares of common stock at $3.60 per share and 1,158,953 pre-funded warrants at $3.599 per warrant with a $0.001 exercise price.
The agreement includes a registration rights requirement to file within 10 days and achieve effectiveness within 90-120 days. The company and insiders agreed to a 60-day lock-up period. WestPark Capital served as placement agent, receiving a 4% fee of gross proceeds plus expense reimbursement.